it went down because it became clear that vancomycin was not as big as an opty as previously thought. Akron has to share revenue with a partner, there are 3 more players on the market inculding a auth. generic and then on friday viropharma filed a suit to get a TRO on vancomycin approval. Combine that with a major improvement in the shortage scenario.
This is headed to 5-6 in next 12 months. Yes, I am short!
You can't possibly believe that Akorn's rise over the past two years has solely been on the expectation on a large revenue stream from generic vanco. 5 bucks? C'mon buddy. Stop trying to strike fear into those who are long.
you may be right......keeping this on a short leash. I would think or have thought that the facts you have laid out would have been known and priced into this stock. Surely, the market knew that they would share revenue and that there were 2 other players waiting on approval? VPHM's move should surprise anyone either since they are trying to hold onto 300 million revs. Just my 2 cents and we have been really weak but pharma in general has seen some selling in the last week. I think they low balled guidance and will actually beat the estimates this Q. Whether that helps the stock is another thing. Thoughts?
Doubtful we go that low. There is no denying the stock has been unusually weak. Normally AKRX has a quick correction and heads back to new highs. And it's not the sector since many pharma and biotech stocks have been fairly strong this year. It could be related to the less than expected earning report.